ArticleScience advances2024
Orally administrated liquid metal agents for inflammation-targeted alleviation of inflammatory bowel diseases.
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Ga(III) ion release from gallium-based liquid metals: The trade-off between efficacy and safety.iScience · 2026Review
- Gallium-Based Liquid Metals: From Properties to Applications.Nanomaterials (Basel, Switzerland) · 2026Review
- Multifunctional Cu-doped MnMaterials today. Bio · 2026Article
- Holmium vanadate nanoparticles as a biosafe and efficient contrast agent for spectral CT imaging of gastritis and colitis.Regenerative biomaterials · 2026Article
- Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Monometal-doped nanozymes ameliorate rheumatoid arthritis by regulating neutrophil ferroptosis via the MDM2-P53-SLC7A11 pathway.Materials today. Bio · 2025Article
- NIR light-driven transformable liquid metal-based nanovaccines restrain postoperative colorectal cancer recurrence.Bioactive materials · 2025Article
- Correlation between depressive-like behavior and gut microbiota in mice with hypothyroidism.World journal of psychiatry · 2025Article
- Orally Administered Functional Polyphenol-Nanozyme-Armored Probiotics for Enhanced Amelioration of Intestinal Inflammation and Microbiota Dysbiosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Liquid Metal Gallium Pharmaceuticals.Theranostics · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid drug clearance and off-target effects of therapeutic drugs can induce low bioavailability and systemic side effects and gravely restrict the therapeutic effects of inflammatory bowel diseases (IBDs). Here, we propose an amplifying targeting strategy based on orally administered gallium (Ga)-based liquid metal (LM) nano-agents to efficiently eliminate reactive oxygen and nitrogen species (RONS) and modulate the dysregulated microbiome for remission of IBDs. Taking advantage of the favorable adhesive activity and coordination ability of polyphenol structure, epigallocatechin gallate (EGCG) is applied to encapsulate LM to construct the formulations (LM-EGCG). After adhering to the inflamed tissue, EGCG not only eliminates RONS but also captures the dissociated Ga to form EGCG-Ga complexes for enhancive accumulation. The detained composites protect the intestinal barrier and modulate gut microbiota for restoring the disordered enteral microenvironment, thereby relieving IBDs. Unexpectedly, LM-EGCG markedly decreases the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.